- cafead Oct 01, 2020 at 10:22: AM
via The FDA has expanded its investigation into AstraZeneca’s COVID-19 vaccine to include data from clinical trials of prophylactics based on the same viral vector platform, Reuters reports.
AstraZeneca quickly gained regulatory clearance to resume dosing in the U.K. part of its development program after a case of transverse myelitis triggered a clinical hold. Regulators in Brazil, India and South Africa have also given AstraZeneca the green light to resume. However, the U.S. phase 3 is still on hold.
article source
AstraZeneca quickly gained regulatory clearance to resume dosing in the U.K. part of its development program after a case of transverse myelitis triggered a clinical hold. Regulators in Brazil, India and South Africa have also given AstraZeneca the green light to resume. However, the U.S. phase 3 is still on hold.
article source